Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Tirzepatide (Mounjaro/Zepbound) may cause slightly more GI side effects overall because it targets two receptors (GLP-1 + GIP), but individual responses vary
Maximum of 1 per order
The Legal Arguments Plaintiffs Claim: Manufacturers (Novo Nordisk, Eli Lilly) knew or should have known about risks of gastroparesis and NAION Warning labels failed to adequately disclose these serious side effects Drugs were aggressively marketed as safe and effective weight loss solutions without proper risk disclosure Patients would not have taken the medications had they known the true risks Defendants Respond: Claims are unfounded (Novo Nordisk statement) Will defend vigorously against lawsuits Motion to dismiss expected January 24, 2025 Argue that labels were adequate and that many conditions may be pre-existing or related to diabetes itself Whos Most at Risk
Ramachandran A, Snehalatha C, Mary S, et al
